Skip to main content
رجوع
ZVRA logo

Zevra Therapeutics, Inc.

جودة البيانات: 100%
ZVRA
NASDAQ Healthcare Biotechnology
KWD 9.15
▼ KWD 0.27 (-2.87%)
القيمة السوقية: 537.21M
نطاق اليوم
KWD 9.03 KWD 9.35
نطاق 52 أسبوعًا
KWD 6.19 KWD 13.16
حجم التداول
663,515
متوسط 50 يوم / 200 يوم
KWD 9.04 / KWD 9.48
الإغلاق السابق
KWD 9.42

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 6.5 0.3
P/B 3.5 2.9
ROE % 85.7 3.7
Net Margin % 78.2 3.8
Rev Growth 5Y % 38.8 10.0
D/E 0.4 0.2

السعر المستهدف للمحللين

Hold
KWD 24.250 +165.0%
Low: KWD 23.000 High: KWD 26.000
مكرر الربحية المستقبلي
19.4
ربحية السهم المستقبلية
KWD 0.487
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
140 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 3.416
KWD 2.997 – KWD 4.416
410 M 5
FY2029 KWD 3.044
KWD 2.671 – KWD 3.936
360 M 2
FY2028 KWD 2.511
KWD 1.600 – KWD 4.360
310 M 7

النقاط الرئيسية

Revenue grew 38.84% annually over 5 years — strong growth
ROE of 85.66% indicates high profitability
Net margin of 78.17% shows strong profitability
Debt/Equity of 0.41 — conservative balance sheet
Negative free cash flow of -2.43M
P/E of 6.45 — trading at a low valuation

النمو

Revenue Growth (5Y)
38.84%
Revenue (1Y)350.91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
85.66%
ROIC-1.46%
Net Margin78.17%
Op. Margin-3.98%

الأمان

Debt / Equity
0.41
Current Ratio5.68
Interest Coverage-0.53

التقييم

P/E Ratio
6.45
P/B Ratio3.47
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 350.91% Revenue Growth (3Y) 96.90%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38.84% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 106.47M Net Income (TTM) 83.23M
ROE 85.66% ROA 29.23%
Gross Margin 84.52% Operating Margin -3.98%
Net Margin 78.17% Free Cash Flow (TTM) -2.43M
ROIC -1.46% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.41 Current Ratio 5.68
Interest Coverage -0.53 Dividend Yield 0.00%
Valuation
P/E Ratio 6.45 P/B Ratio 3.47
P/S Ratio 5.05 PEG Ratio -0.04
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 537.21M Enterprise Value 538.01M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 106.47M 23.61M 27.46M 10.16M 28.65M
Net Income 83.23M -105.51M -46.05M -26.77M -8.56M
EPS (Diluted) 1.35 -2.28 -1.30 -0.78 -2.11
Gross Profit 89.99M 16.20M 24.52M 9.94M 26.59M
Operating Income -4.23M -87.00M -49.60M -42.57M 7.73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 284.73M 178.13M 172.33M 115.34M 132.94M
Total Liabilities 130.07M 138.46M 110.46M 40.22M 5.82M
Shareholders' Equity 154.66M 39.67M 61.86M 75.12M 127.12M
Total Debt 63.21M 60.30M 43.77M 18.78M 1.61M
Cash & Equivalents 62.41M 33.79M 43.05M 65.47M 112.35M
Current Assets 223.01M 86.03M 86.94M 92.83M 115.06M
Current Liabilities 39.28M 34.07M 73.72M 12.02M 4.23M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026